用於在活體外培養口腔黏膜上皮祖細胞以及口腔黏膜上皮細胞的方法

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

106107887

專利證號

I 627280

專利獲證名稱

用於在活體外培養口腔黏膜上皮祖細胞以及口腔黏膜上皮細胞的方法

專利所屬機關 (申請機關)

長庚醫療財團法人

獲證日期

2018/06/21

技術說明

2004年日本學者首先提出，以培養之自體口腔黏膜上皮細胞替代角膜上皮細胞 (cultivated oral mucosal epithelial transplantation, COMET)以治療眼表層疾病。我們亦已於2006~2009年進行了衛生署核准之第一期人體實驗計畫。在第一期的計畫中，我們已證實此替代性細胞療法，對促進重度眼表層灼傷患者傷口之癒合很有幫助(Ma DHK et al. Eye 2009;23:1442-1450)；我們亦發現移植後口腔黏膜上皮細胞得以長久存在於眼角膜(Chen HCJ et al. Invest Ophthalmol Vis Sci 2009;50:4660-4668)，從而確認此一創新手術乃為有效之療法。最近我們再發現由於抑制角膜新生血管較差，COMET手術較適用於促進角膜癒傷反應(Chen HCJ et al. Invest Ophthalmol Vis Sci 2012;53:5615–5623)。同時，我們已證明本院培養細胞之製程，可以合乎GTP之要求，並通過衛生署及所屬機關之認證。 Japanese scholars proposed novel protocols for treatment of ocular surface diseases with cultivated oral mucosal epithelial transplantation (COMET) in 2004. From 2006 to 2009, we have also executed a phase I clinical trial approved by TFDA. In the phase I trial, we have substantiated considerable efficacy of such replacement cell therapy in promoting wound healing in patients with severe ocular surface burns. We have also identify long-term persistence of transplanted oral mucosal epithelial cells in the cornea, justifying such innovative surgical procedure as an effective treatment modality. Recently, we further concluded that COMET is more suitable in promoting corneal wound healing due to its inferior inhibitory effect on corneal neovascularization. Meanwhile, we have demonstrated that our protocols in cell culture meet the GTP standards, and passed the accreditation of TFDA and affiliated institutes.